维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

19篇 您的检索式：作者名="Lisa K D"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Leptin is a four - helix bundle:secondary structure by NMR显示文摘	Allen D K Gerald W B Lisa M C	1997	FEBS Letters1997，407，2：	1
	2	Development of an attachment-informed measure of sexual behavior in late adolescence显示文摘	Szielasko A L Symons D K Lisa Price E	2013	Journal of ado- lesc-ence2013，36，2：	1
	3	Pectin induces apoptosis in human prostate cancer cell:correlation of apoptotic function with pectin structure显示文摘	Crystal L J Tina M D Lisa K T	2007	Glyeobiology2007，17，8：	1
	4	Structure-based design: synthesis and biological evaluation of a series of novel cycloamide- derived HIV-1 protease inhibitors 显示文摘	Arun K Ghosh Lisa M Swanson Hanna Cho Sofiya Leshehenko Khaja Azhar Hussain Stephanie Kay D Eric Walters Yasuhiro Koh Hiroaki Mitsuya	2005	Journal of medicinal chemistry2005，48，10：	1
	5	Arteriovenous malformations in mice lacking activin roceptor-like kinase-1 显示文摘	Lisa D Umess BA Lise K	2000	Nat Genet2000，26，11：	1
	6	Syntheses of 4'epi-antino-4'-deoxyavermectins B1显示文摘	Raymond J C Dennis H K Lisa M D	1994	J Org Chem1994，59，：	1
	7	Management Earnings Forecasts:A Review and Framework显示文摘	HIRST D LISA K VENKATARAMAN S	2008	Accounting Horizons2008，22，：	1
	8	Identification of a novel cleavage activity of the first papain-like proteinase domain encoded by open reading frame 1a of the coronavirus avian infectious bronchitis virus and characterization of the cleavage products显示文摘	Lim K P Lisa F P Liu D X		J Virolo0，，：	1
	9	18F-FDG kinetics in locally advanced breast cancer:correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy显示文摘	Jeffrey T Lisa K D Erin K S	2004	J Nucl Med2004，45，11：	1
	10	Membrane association of functional vesicular stomatitis virus matrix protein in vivo显示文摘	John K R	1993	J Virol1993，67，：	1
	11	Nutrional importance of Pyrroloquinoline quinone显示文摘	John K Carsten S Lisa D	1989	Science1989，245，：	1
	12	Arteriovenous malfor-mations in mice lacking activin receptor-like kinase-1显示文摘	Lisa D Urness BA Lise K	2000	Nat Genet2000，26，11：	1
	13	Risk of rehospitaliation for patients using Clopidogrel with a Proton Pump Inhibitor显示文摘	Stockl K M Pharm D Lisa Le M S	2010	Arch Intern Med2010，170，8：	1
	14	18F-FDG kinetics in locally advanced breast cancer correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy 显示文摘	JEFFREY T LISA K D ERIN K S	2004	J Nucl Med2004，45，11：	1
	15	Stability of palladium-based catalysts during catalytic combustion of methane 显示文摘	Persson K Pfefferle Lisa D Schwartz W	2007	Applied Catalysis A2007，74，34：	1
	16	Functional self-efficacy and pain-related disability among oler veterans with chronic pain in a primary care setting显示文摘	Lisa C B Guo Zh-Ch Robert D K	2003	Pain2003，104，1：	1
	17	Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-L-Lysine Dendrimers 显示文摘	Lisa M K Brian D K Victoria M M	2009	Mol Pharmaceutics2009，，6：	1
	18	A tunablehydrogel for encapsulation and controlled release ofbioactive proteins显示文摘	Mercedes D Carsten S Lisa D K	2002	Biomacromolecules2002，3，：	1
	19	Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio,not age显示文摘Recent guidelines restricted aspirin(ASA)in primary prevention of cardiovascular disease(CVD)to patients<70 years old and more recent guidance to<60.In the most comprehensive prior meta-analysis,the Antithrombotic Trialists Collaboration reported a significant 12%reduction in CVD with similar benefit−risk ratios at older ages.Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines,four trials were added to an updated meta-analysis.ASA produced a statistically significant 13%reduction in CVD with 95%confidence limits(0.83 to 0.92)with similar benefits at older ages in each of the trials.Primary care providers should make individual decisions whether to prescribe ASA based on benefit−risk ratio,not simply age.When the absolute risk of CVD is>10%,benefits of ASA will generally outweigh risks of significant bleeding.ASA should be considered only after implementation of therapeutic lifestyle changes and other drugs of proven benefit such as statins,which are,at the very least,additive to ASA.Our perspective is that individual clinical judgements by primary care providers about prescription of ASA in primary prevention of CVD should be based on our evidence-based solution of weighing all the absolute benefits and risks rather than age.This strategy would do far more good for far more patients as well as far more good than harm in both developed and developing countries.This new and novel strategy for primary care providers to consider in prescribing ASA in primary prevention of CVD is the same as the general approach suggested by Professor Geoffrey Rose decades ago.	Kyungmann Kim Charles H Hennekens Lisa Martinez J Michael Gaziano Marc A Pfeffer Bianca Biglione Alexander Gitin Jeanne Bell McCabe Thomas D Cook David L DeMets Sarah K Wood	2021	Family Medicine and Community Health2021，9，4：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费